Navigation Links
YM Biosciences To Present Poster On CYT387 At The European School Of Haematology International Conference
Date:10/1/2010

inistered inhibitor of both the JAK1 and JAK2 kinase enzymes, which have been implicated in a number of immune cell disorders including myeloproliferative disorders and inflammatory diseases as well as certain cancers. CYT387 is currently in a Phase I/II trial in myelofibrosis with detailed initial safety and activity data expected at the American Society of Hematology (ASH) meeting in December 2010. Nimotuzumab is a humanized monoclonal antibody targeting EGFR with a potential best-in-class side effect profile. Nimotuzumab is being evaluated in numerous Phase II and III trials worldwide by YM's licensees. CYT997 is a uniquely orally-available agent with dual mechanisms of vascular disruption and cytotoxicity, and is currently in a Phase II trial for glioblastoma multiforme. In addition to YM's three clinical stage products, the Company has a library of more than 4,000 novel compounds identified through internal research conducted at YM BioSciences Australia which are currently being evaluated.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. YM BioSciences licensee Pulmokine awarded NIH funding to develop small molecule drugs for pulmonary hypertension
2. YM BioSciences reports fiscal year end 2010 operational and financial results
3. Regado Biosciences to Present at the UBS Global Life Sciences Conference on September 22, 2010 in New York City
4. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
5. Cardio3 BioSciences Publishes the Science Basis for C-Cure(R) in JACC
6. Signum Biosciences Names Braham Shroot as Chief Executive Officer
7. YM BioSciences announces conclusion of Phase I dose-escalation and expansion of ongoing CYT387 Phase I/II clinical study
8. CORRECTED: Ampio Pharmaceuticals Announces Completion of Negotiations for Acquisition of DMI BioSciences, Inc.
9. Ambit Biosciences Announces Transition in Company Leadership
10. Sangamo BioSciences Announces Second Quarter 2010 Conference Call and Webcast
11. Calithera Biosciences Closes $40 Million in Series A Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014 Dublin ... has announced the addition of the  "Micro Market ... their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... the fastest-growing segments in the chromatography market. The ... and expected to reach $2.0 billion by 2019, ...
(Date:9/19/2014)... -- The new , Healthcare and Life Sciences ... on PharmaBoardroom.com for free download , looks ... Spanish economy in 2009, and the austerity measures that followed, ... in times of trouble. "Despite the crisis, ... market, and the general conditions to invest are favorable to ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 ... urological and interventional radiology products and services, announced ... as cryotherapy and cryoablation) versus external beam radiotherapy ... of the American Urological Association (MAAUA) Annual Meeting ... "Comparing Relative Effectiveness of Cryosurgery and External Beam ...
(Date:9/18/2014)... , Sept. 18, 2014 /PRNewswire-iReach/ -- DeepResearchReports.com ... China Acetic Acid Industry" and "2014 Deep Research ... reports to its research database. Photo ... Deep Research Report on Global and China Acetic ... report on China and ...
Breaking Biology Technology:Micro Market Monitor : Global Pre-packed Chromatography Columns 2PharmaBoardroom Releases New Spain Pharmaceuticals Report 2PharmaBoardroom Releases New Spain Pharmaceuticals Report 3HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 2Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 3Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 4
... Calif., May 20 Beckman Coulter, Inc. (NYSE: ... of products that simplify, automate and innovate complex biomedical ... of shares of its common stock, the proceeds of ... the previously announced acquisition of the diagnostic systems portion ...
... - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI ... partner, Boston Scientific Corporation (NYSE: BSX ... of patients with left main coronary disease who ... Stent System. SYNTAX-LE MANS is a substudy of ...
... In an eleventh-hour attempt to smear Ted Karkus, The ... press release claiming that there was some improper financial arrangement ... subsidiary of Quigley, and Mr. Ted Karkus, who leads a ... of Quigley,s Board of Directors for election at the annual ...
Cached Biology Technology:Beckman Coulter, Inc. Announces Pricing of Common Stock Offering 2Beckman Coulter, Inc. Announces Pricing of Common Stock Offering 3SYNTAX substudy shows positive outcomes for left main patients treated with TAXUS(R) Express(2)(R) Stent System 2SYNTAX substudy shows positive outcomes for left main patients treated with TAXUS(R) Express(2)(R) Stent System 3SYNTAX substudy shows positive outcomes for left main patients treated with TAXUS(R) Express(2)(R) Stent System 4SYNTAX substudy shows positive outcomes for left main patients treated with TAXUS(R) Express(2)(R) Stent System 5In Eleventh-Hour Smear Attempt, Quigley Management Sacrifices Key Employee of its Pharma Division 2In Eleventh-Hour Smear Attempt, Quigley Management Sacrifices Key Employee of its Pharma Division 3
(Date:9/18/2014)... located deep in the primitive brainstem has revealed how ... Harvard School of Medicine and the University at Buffalo ... the second "sleep node" identified in the mammalian brain ... to produce deep sleep. , Published online in August ... fully half of all of the brain,s sleep-promoting activity ...
(Date:9/18/2014)... novel robotic system that can operate inside the bore ... part of a biomedical research partnership program at Brigham ... determining if the robot, in conjunction with real-time MRI ... less costly, and less discomforting for the patient. The ... cancer therapies with greater precision. , Developed by a ...
(Date:9/18/2014)... No matter how many times it,s demonstrated, it,s ... creatures. , But by using a signaling ... alter their behavior to suit their population. In ... are present, and act accordingly. , Once the ... may change from innocuous to pathogenic, or from ...
Breaking Biology News(10 mins):No sedative necessary: Scientists discover new 'sleep node' in the brain 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3
... female frogs in a tiny rainforest outpost of Australia ... 8,000 years or less, according to scientists from the ... the Queensland Parks and Wildlife Service. , "That's lightning-fast," ... UC Berkeley and director of the Museum of Vertebrate ...
... culminated in a study published in this week's Science that ... or prevent East Coast fever. , The disease, which kills ... has had a devastating impact on rural areas ?such as ... role in the local society and economies. The fever is ...
... a single gene can result in two immune ... frequent or unusually severe infections, according to new ... Genetics. The discovery may lead to new diagnostic ... (IgA) deficiency and common variable immunodeficiency (CVID). Currently, ...
Cached Biology News:Picky female frogs drive evolution of new species in less than 8,000 years 2Picky female frogs drive evolution of new species in less than 8,000 years 3Picky female frogs drive evolution of new species in less than 8,000 years 4US/African project deciphers deadly parasite genome 2US/African project deciphers deadly parasite genome 3Defective Gene Linked to Two Inherited Immune Deficiencies 2Defective Gene Linked to Two Inherited Immune Deficiencies 3
Anti-Indolamine (Indoleamine) 2,3-dioxygenase Immunogen: Recombinant human IDO. Available Date: 38454...
Anti-Ephrin B1 Host: rabbit polyclonal Species Reactivity: human Applications: WB Storage: 4C...
Human Regulatory T cell Staining Kit #2 (w/ APC Foxp3 PCH101, FITC CD4, PE CD25)...
...
Biology Products: